BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stavraka C, Rush H, Ross P. Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions. J Hepatocell Carcinoma. 2019;6:11-21. [PMID: 30643759 DOI: 10.2147/JHC.S159805] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Ayas MF, Affas S, Ayas Z, Chand M, Hadid T. Primary Combined Hepatocellular-Cholangiocarcinoma: A Case of Underdiagnosed Primary Liver Cancer. Cureus 2021;13:e18224. [PMID: 34703709 DOI: 10.7759/cureus.18224] [Reference Citation Analysis]
2 Raevskaya O, Appelman H, Razumilava N. A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma. Curr Hepatol Rep 2020;19:478-85. [PMID: 33415066 DOI: 10.1007/s11901-020-00556-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Peng Y, Lin P, Wu L, Wan D, Zhao Y, Liang L, Ma X, Qin H, Liu Y, Li X, Wang X, He Y, Yang H. Ultrasound-Based Radiomics Analysis for Preoperatively Predicting Different Histopathological Subtypes of Primary Liver Cancer. Front Oncol 2020;10:1646. [PMID: 33072550 DOI: 10.3389/fonc.2020.01646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Badar W, Van Ha T, Zangan S, Navuluri R, Pillai A, Baker T, Ahmed O. Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma. Gastrointest Tumors 2020;7:144-50. [PMID: 33173778 DOI: 10.1159/000508386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Wang X, Wang S, Yin X, Zheng Y. MRI-based radiomics distinguish different pathological types of hepatocellular carcinoma. Comput Biol Med 2021;:105058. [PMID: 34836622 DOI: 10.1016/j.compbiomed.2021.105058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:139-152. [PMID: 31792430 DOI: 10.1038/s41575-019-0229-4] [Cited by in Crossref: 226] [Cited by in F6Publishing: 203] [Article Influence: 75.3] [Reference Citation Analysis]
7 Perng DS, Hung CM, Lin HY, Morgan P, Hsu YC, Wu TC, Hsieh PM, Yeh JH, Hsiao P, Lee CY, Li YC, Wang YC, Chen YS, Lin CW. Role of autophagy-related protein in the prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgical resection. BMC Cancer 2021;21:828. [PMID: 34273969 DOI: 10.1186/s12885-021-08553-6] [Reference Citation Analysis]
8 Kim M, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Hong SM. Postresection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma according to the 2010 World Health Organization classification: single-center experience of 168 patients. Ann Surg Treat Res 2021;100:260-9. [PMID: 34012943 DOI: 10.4174/astr.2021.100.5.260] [Reference Citation Analysis]
9 Kasprzak A, Adamek A. Mucins: the Old, the New and the Promising Factors in Hepatobiliary Carcinogenesis. Int J Mol Sci 2019;20:E1288. [PMID: 30875782 DOI: 10.3390/ijms20061288] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
10 Zhou Y, Yin S, Zhao L, Zhang X, Li M, Ding J, Yan K, Jing X. CEUS and CT/MRI LI-RADS in Association With Serum Biomarkers for Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma. Front Oncol 2022;12:897090. [PMID: 35651804 DOI: 10.3389/fonc.2022.897090] [Reference Citation Analysis]
11 Zhou YW, Li QF, Chen YY, Wang K, Pu D, Chen XR, Li CH, Jiang L, Wang Y, Li Q, Yang Y, Gou HF, Bi F, Liu JY, Chen Y, Qiu M. Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on SEER database and validation in multicenter study. Eur J Surg Oncol 2022:S0748-7983(22)00065-8. [PMID: 35115213 DOI: 10.1016/j.ejso.2022.01.023] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gao L, Huang JY, Lu ZJ, Lu Q. Contrast-enhanced ultrasound manifestations of synchronous combined hepatocellular-cholangiocarcinoma and hepatocellular carcinoma: A case report. World J Clin Cases 2022; 10(11): 3615-3623 [DOI: 10.12998/wjcc.v10.i11.3615] [Reference Citation Analysis]
13 Sun W, Hu C, Wang T, Wang J, Zhang J, Gao F, Ou Q, Tian H, Jin C, Xu J, Zhang J, Xu GT, Lu L. Glia Maturation Factor Beta as a Novel Biomarker and Therapeutic Target for Hepatocellular Carcinoma. Front Oncol 2021;11:744331. [PMID: 34796110 DOI: 10.3389/fonc.2021.744331] [Reference Citation Analysis]
14 Kim SH, Navot B, Guniganti P, Gavlin A, Hecht EM, Kierans AS. Liver Transplant for Non-Hepatocellular Malignancies: A Review for Radiologists. AJR Am J Roentgenol 2022. [PMID: 35544376 DOI: 10.2214/AJR.22.27783] [Reference Citation Analysis]
15 Ishii T, Ito T, Sumiyoshi S, Ogiso S, Fukumitsu K, Seo S, Taura K, Uemoto S. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma. World J Surg Oncol 2020;18:319. [PMID: 33276780 DOI: 10.1186/s12957-020-02099-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Swed B, Gandarilla O, Chiu K, Halazun KH, Samstein B, Yantiss R, Brar G. Rare Histological Variants of Liver Cancer and Their Management: A Single-Institution Experience. Case Reports Hepatol 2021;2021:6654229. [PMID: 33968454 DOI: 10.1155/2021/6654229] [Reference Citation Analysis]
17 Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines (Basel) 2021;9:422. [PMID: 33922362 DOI: 10.3390/vaccines9050422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhao Q, Molina-Portela MDP, Parveen A, Adler A, Adler C, E H, Wang W, Ni M, Wei Y, Atwal G, Mohrs M, Thurston G, Eichten A. Heterogeneity and chimerism of endothelial cells revealed by single-cell transcriptome in orthotopic liver tumors. Angiogenesis 2020;23:581-97. [PMID: 32440964 DOI: 10.1007/s10456-020-09727-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
19 Wang T, Yang X, Tang H, Kong J, Shen S, Qiu H, Wang W. Integrated nomograms to predict overall survival and recurrence-free survival in patients with combined hepatocellular cholangiocarcinoma (cHCC) after liver resection. Aging (Albany NY) 2020;12:15334-58. [PMID: 32788423 DOI: 10.18632/aging.103577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Azizi AA, Hadjinicolaou AV, Goncalves C, Duckworth A, Basu B. Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma. Front Oncol 2020;10:570958. [PMID: 33102226 DOI: 10.3389/fonc.2020.570958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Su YL, Ng CT, Jan YH, Hsieh YL, Wu CL, Tan KT. Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation. Onco Targets Ther 2021;14:3895-901. [PMID: 34234458 DOI: 10.2147/OTT.S317514] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Hou GM, Liu HL, Wu H, Zeng Y. Prediction of Prognosis for cHCC-CC Patients After Surgery: Comparison of Tumor Marker Score Based on AFP, CEA, CA19-9, and Other Clinical Stages. Ann Surg Oncol 2021. [PMID: 33900502 DOI: 10.1245/s10434-021-09949-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Gentile D, Donadon M, Lleo A, Aghemo A, Roncalli M, di Tommaso L, Torzilli G. Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review. Liver Cancer 2020;9:15-27. [PMID: 32071906 DOI: 10.1159/000503719] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
24 Renzulli M, Ramai D, Singh J, Sinha S, Brandi N, Ierardi AM, Albertini E, Sacco R, Facciorusso A, Golfieri R. Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma. Cancers (Basel) 2021;13:3336. [PMID: 34283065 DOI: 10.3390/cancers13133336] [Reference Citation Analysis]
25 Brandi G, Tavolari S. Asbestos and Intrahepatic Cholangiocarcinoma. Cells 2020;9:E421. [PMID: 32059499 DOI: 10.3390/cells9020421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
26 Liu T, Li S, Wu L, Yu Q, Li J, Feng J, Zhang J, Chen J, Zhou Y, Ji J, Chen K, Mao Y, Wang F, Dai W, Fan X, Wu J, Guo C. Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2. J Hepatocell Carcinoma 2020;7:19-31. [PMID: 32110554 DOI: 10.2147/JHC.S237614] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
27 Azees PAA, Natarajan S, Amaechi BT, Thajuddin N, Raghavendra VB, Brindhadevi K, Pugazhendhi A. An empirical review on the risk factors, therapeutic strategies and materials at nanoscale for the treatment of oral malignancies. Process Biochemistry 2022. [DOI: 10.1016/j.procbio.2022.04.013] [Reference Citation Analysis]
28 Zherebtsov EA, Potapova EV, Mamoshin AV, Shupletsov VV, Kandurova KY, Dremin VV, Abramov AY, Dunaev AV. Fluorescence lifetime needle optical biopsy discriminates hepatocellular carcinoma. Biomed Opt Express 2022;13:633. [DOI: 10.1364/boe.447687] [Reference Citation Analysis]
29 Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, Dai W, Guo C. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res 2020;39:126. [PMID: 32631382 DOI: 10.1186/s13046-020-01629-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 11.5] [Reference Citation Analysis]
30 Dimopoulos YP, Winslow ER, He AR, Ozdemirli M. Hepatocellular carcinoma with biliary and neuroendocrine differentiation: A case report. World J Clin Oncol 2021; 12(4): 262-271 [PMID: 33959479 DOI: 10.5306/wjco.v12.i4.262] [Reference Citation Analysis]
31 Murugesan K, Sharaf R, Montesion M, Moore JA, Pao J, Pavlick DC, Frampton GM, Upadhyay VA, Alexander BM, Miller VA, Javle MM, Bekaii Saab TS, Albacker LA, Ross JS, Ali SM. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. JCO Precis Oncol 2021;5:PO. [PMID: 34476330 DOI: 10.1200/PO.20.00397] [Reference Citation Analysis]